SG/CALL/AMGEN/380/0.1/21.06.24 | Market Closed - Boerse Frankfurt Warrants 09:01:37 14/06/2024 BST | ||
| 0.001 EUR | 0.00% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.001 | 0.00% |
| 13/06/24 | 0.001 | 0.00% |
| 12/06/24 | 0.001 | 0.00% |
| 11/06/24 | 0.001 | 0.00% |
| 10/06/24 | 0.001 | 0.00% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 09:01 am
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| WKN | SU6V4H |
| ISIN | DE000SU6V4H0 |
| Date issued | 10/01/2024 |
| Strike | 380 $ |
| Maturity | 21/06/2024 (5 Days) |
| Parity | 10 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.44 € |
|---|---|
| Lowest since issue | 0.001 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 0.7855 |
| Difference Strike | 81.38 $ |
| Difference Strike % | +21.42% |
| Intrinsic value | 0.000000 |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
298.6
USD
Average target price
316.4
USD
Spread / Average Target
+5.97%
- Stock Market
- Warrants
- Warrant
